Evidence map›Paper›PMID 21719783›Full record

Trial reportJournal of the American Society of Nephrology : JASN2011

Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease.

Michelle P Kao, Donald S Ang, Stephen J Gandy, M Adnan Nadir, J Graeme Houston, Chim C Lang, Allan D Struthers

3 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 100 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 15 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01951404 phase4completednot on this mapstarted 2013, after this paper: background citation

Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study

TypeinterventionalSponsorUniversity of DundeeRan2013 to 2016Enrolled80ConditionsEnd Stage Renal Disease, Left Ventricular HypertrophyArmsAllopurinol, Placebo (for allopurinol)
NCT03353298 phase2completednot on this mapstarted 2018, after this paper: background citation

A Randomized, Double-blind, Placebo-controlled, 9-month, Parallel Group Study of Allopurinol to Reduce Left Ventricular Mass in Living Kidney Donors (AL-DON)

TypeinterventionalSponsorOslo University HospitalRan2018 to 2020Enrolled71ConditionsRenal Transplant Donor of Left Kidney, Renal Transplant Donor of Right KidneyArmsAllopurinol 300 mg, Placebo Oral Tablet
NCT03700645 phase4unknown statusnot on this mapstarted 2018, after this paper: background citation

Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study

TypeinterventionalSponsorTel-Aviv Sourasky Medical CenterRan2018 to 2020Enrolled100ConditionsDiabetes Mellitus, Ischemic Heart Disease, Multi Vessel Coronary Artery DiseaseArmsAllopurinol
3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 15 syntheses or guidelines pooled it, 227 citations in OpenAlex.

  1. Pooled it
  2. Efficacy of Allopurinol in Improving Endothelial Dysfunction: A Systematic Review and Meta-Analysis.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Effects of Allopurinol on Arterial Stiffness: A Meta-Analysis of Randomized Controlled Trials.Medical science monitor : international medical journal of experimental and clinical research · 2016
    Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Allopurinol in Patients with Pulmonary Hypertension Associated with Chronic Lung Disease.International journal of chronic obstructive pulmonary disease · 2020
    Trial

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Michelle P KaoDivision of Medical Sciences, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom. mpckao@doctors.org.uk
Donald S Ang
Stephen J Gandy
M Adnan Nadir
J Graeme Houston
Chim C Lang
Allan D Struthers
Ninewells Hospital · GBUniversity of Dundee · GB

Funding

British Heart Foundation
6 · The paper itself

Abstract

Allopurinol ameliorates endothelial dysfunction and arterial stiffness among patients without chronic kidney disease (CKD), but it is unknown if it has similar effects among patients with CKD. Furthermore, because arterial stiffness increases left ventricular afterload, any allopurinol-induced improvement in arterial compliance might also regress left ventricular hypertrophy (LVH). We conducted a randomized, double-blind, placebo-controlled, parallel-group study in patients with stage 3 CKD and LVH. We randomly assigned 67 subjects to allopurinol at 300 mg/d or placebo for 9 months; 53 patients completed the study. We measured left ventricular mass index (LVMI) with cardiac magnetic resonance imaging (MRI), assessed endothelial function by flow-mediated dilation (FMD) of the brachial artery, and evaluated central arterial stiffness by pulse-wave analysis. Allopurinol significantly reduced LVH (P=0.036), improved endothelial function (P=0.009), and improved the central augmentation index (P=0.015). This study demonstrates that allopurinol can regress left ventricular mass and improve endothelial function among patients with CKD. Because LVH and endothelial dysfunction associate with prognosis, these results call for further trials to examine whether allopurinol reduces cardiovascular events in patients with CKD and LVH.

Indexed as

AgedAllopurinolAntimetabolitesDouble-Blind MethodEndothelium, VascularFemaleHumansHypertrophy, Left VentricularMaleMiddle AgedRenal Insufficiency, ChronicXanthine OxidaseAllopurinolAntimetabolitesXanthine Oxidase

Identifiers

PMID21719783
PMCPMC3137586
OpenAlexW2111333427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.